Pharmaceutical Sciences Research Centre, Shiraz University of Medical Sciences, P.O. Box 71468-64685, Shiraz, Iran.
Recent Pat Biotechnol. 2021 Oct 4;15(2):137-147. doi: 10.2174/1872208315666210419102117.
Nowadays, the CRISPR-Cas9 genome editing system has become a popular bioengineering-based tool for various applications. Owing to its high-target specificity, efficiency, versatility, and simplicity, it has gained attention as a robust tool for molecular biology research, which unveils the biological functions of unexplored genes and engineers the metabolic pathways. Chinese hamster ovary (CHO) cells and Escherichia coli are regarded as the most commonly used expression platforms for industrial- scale production of recombinant proteins. The emergence of the CRISPR-Cas9 genome editing system promotes the current status of expression hosts towards controllable and predictable strains.
This paper presents the current status of expression hosts for biopharmaceutical production. Some major accomplishments in the utilization of the CRISPR-Cas9 genome editing tool in the different prokaryotic and eukaryotic systems are discussed, and more importantly, the future directions of this newly arrived technology to make the next-generation cell factories with improved or novel properties are suggested. Moreover, the challenges faced in recent patents in this field are also discussed.
The CRISPR-Cas9 genome-editing tool has been adopted to be utilized in some major expression platforms. CRISPeering has been successfully employed for genome editing in different prokaryotic and eukaryotic host cells. The emergence of systems metabolic engineering, systems biology, and synthetic biology fortify the current situation of the CRISPR-Cas9 genome editing system.
如今,CRISPR-Cas9 基因组编辑系统已成为各种应用中流行的基于生物工程的工具。由于其高靶向特异性、高效率、多功能性和简单性,它已作为分子生物学研究的强大工具引起关注,揭示了未探索基因的生物学功能并设计代谢途径。中国仓鼠卵巢 (CHO) 细胞和大肠杆菌被认为是用于工业规模生产重组蛋白的最常用表达平台。CRISPR-Cas9 基因组编辑系统的出现推动了表达宿主向可控和可预测菌株的当前状态发展。
本文介绍了生物制药生产的表达宿主的现状。讨论了 CRISPR-Cas9 基因组编辑工具在不同原核和真核系统中的一些主要应用成果,更重要的是,提出了这项新技术在未来的发展方向,以制造具有改进或新颖特性的下一代细胞工厂。此外,还讨论了该领域最近专利中面临的挑战。
CRISPR-Cas9 基因组编辑工具已被用于一些主要的表达平台。CRISPeering 已成功用于不同原核和真核宿主细胞的基因组编辑。系统代谢工程、系统生物学和合成生物学的出现增强了 CRISPR-Cas9 基因组编辑系统的现状。